Emcure Pharmaceuticals Ltd. Financials: Quarterly Results
Revenue
2365.33
Cr.
PAT
231.37
Cr.
EBITDA
389.92
Cr.
Emcure Pharmaceuticals Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 2363.48 | 2269.82 | 2100.54 | 2116.25 | 1962.63 |
| Total Income From Operations (Cr.) | 2363.48 | 2269.82 | 2100.54 | 2116.25 | 1962.63 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 389.92 | 373.96 | 321.01 | 310.02 | 261.70 |
| P/L Before Exceptional Items & Tax (Cr.) | 351.94 | 341.42 | 294.26 | 270.99 | 229.92 |
| P/L After Tax from Ordinary Activities (Cr.) | 231.37 | 251.37 | 214.79 | 197.24 | 156.09 |
| Net Profit/Loss For the Period (Cr.) | 231.37 | 251.37 | 214.79 | 197.24 | 156.09 |
| Basic EPS | 12.16 | 12.85 | 10.92 | 9.97 | 8.12 |
FAQs
Emcure Pharmaceuticals Ltd. announced its quarterly results for Q3 FY2026 on February 4, 2026.
In Q3 FY2026, Emcure Pharmaceuticals Ltd. are as follows:
Revenue: ₹2365.33 crore
Net Profit: ₹231.37 crore.
For Q3 FY2026, Emcure Pharmaceuticals Ltd. posted ₹2365.33 crore in revenue and ₹231.37 crore in net profit.
Past quarterly results for Emcure Pharmaceuticals Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.